国家放射与治疗临床医学研究中心,《经皮冠状动脉介入治疗术后口服抗栓策略优化专家共识》专家组,吴鸿谊

• 1:复旦大学附属中山医院

摘要(Abstract)：

在经皮冠状动脉介入治疗取得成功后，规范的口服抗栓药物管理成为保障患者长期预后的关键一环。抗栓治疗是把双刃剑，在降低血栓及缺血事件发生风险的同时，也带来了出血风险的增加。如何在缺血与出血风险之间进行权衡，找到最佳的平衡点，一直是临床医师高度关注且亟待解决的难题。鉴于患者个体间风险特征与对药物反应存在差异，指南推荐的常规策略不一定是适合患者的最优策略。近年来，大量临床研究聚焦于不同人群适宜抗栓策略的探索，为指南与共识的更新提供了证据基础，也为临床实践开辟了多元治疗路径。然而，在患者评估、调整时机和策略制订等方面尚欠缺规范性和灵活性，亟需专业共识予以指导。本共识紧密围绕临床实际需求，强调动态评估全程管理，聚焦个体差异，兼顾患者依从性，旨在为临床实践提供具有实操性的优化抗栓方案选择，切实改善患者的长期预后。

关键词(KeyWords)： 经皮冠状动脉介入治疗;抗血小板治疗;口服抗凝药物

Abstract:

Keywords:

基金项目(Foundation): 四大慢病重大专项项目（2025ZD0546600、2025ZD0546603）;; 上海市重中之重研究中心建设项目（2022ZZ01010）;; 国家自然科学基金项目（82570396）

作者(Author): 国家放射与治疗临床医学研究中心,《经皮冠状动脉介入治疗术后口服抗栓策略优化专家共识》专家组,吴鸿谊

参考文献(References)：

• [1]Kamran H,Jneid H,Kayani WT,et al.Oral antiplatelet therapy after acute coronary syndrome:a review[J].JAMA,2021,325(15):1545-1555.DOI:10.1001/jama.2021.0716.
• [2]Byrne RA,Rossello X,Coughlan JJ,et al.2023 ESC Guidelines for the management of acute coronary syndromes[J].Eur Heart J,2023,44(38):3720-3826.DOI:10.1093/eurheartj/ehad191.
• [3] Vrints C,Andreotti F,Koskinas KC,et al.2024 ESC Guidelines for the management of chronic coronary syndromes[J].Eur Heart J,2024,45(36):3415-3537.DOI:10.1093/eurheartj/ehae177.
• [4] Valgimigli M,Bueno H,Byrne RA,et al.2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS:the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology(ESC)and of the European Association for Cardio-Thoracic Surgery(EACTS)[J].Eur Heart J,2018,39(3):213-260.DOI:10.1093/eurheartj/ehx419.
• [5]Eikelboom JW,Connolly SJ,Bosch J,et al.Rivaroxaban with or without aspirin in stable cardiovascular disease[J].N Engl J Med,2017,377(14):1319-1330.DOI:10.1056/NEJMoa1709118.
• [6]Cho MS,Kang DY,Ahn JM,et al.Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease[J].N Engl J Med,2024,391(22):2075-2086.DOI:10.1056/NEJMoa2407362.
• [7]Yasuda S,Kaikita K,Akao M,et al.Antithrombotic therapy for atrial fibrillation with stable coronary disease[J].N Engl J Med,2019,381(12):1103-1113.DOI:10.1056/NEJMoa1904143.
• [8]Gibson CM,Mehran R,Bode C,et al.Prevention of bleeding in patients with atrial fibrillation undergoing PCI[J].N Engl J Med,2016,375(25):2423-2434.DOI:10.1056/NEJMoa1611594.
• [9]Cannon CP,Bhatt DL,Oldgren J,et al.Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation[J].N Engl J Med,2017,377(16):1513-1524.DOI:10.1056/NEJMoa1708454.
• [10]Lopes RD,Heizer G,Aronson R,et al.Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation[J].N Engl J Med,2019,380(16):1509-1524.DOI:10.1056/NEJMoa1817083.
• [11]Vranckx P,Valgimigli M,Eckardt L,et al.Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation(ENTRUST-AF PCI):a randomised,open-label,phase 3b trial[J].Lancet,2019,394(10206):1335-1343.DOI:10.1016/S0140-6736(19)31872-0.
• [12]Patrono C.Aspirin as an antiplatelet drug[J].N Engl J Med,1994,330(18):1287-1294.DOI:10.1056/NEJM199405053301808.
• [13]Antithrombotic Trialists'Collaboration.Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death,myocardial infarction,and stroke in high risk patients[J].BMJ,2002,324(7329):71-86.DOI:10.1136/bmj.324.7329.71.
• [14]Patrono C.Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease[J].Eur Heart J,2024,45(27):2362-2376.DOI:10.10 9 3/eurheartj/ehae324.
• [15]Baigent C,Blackwell L,Collins R,et al.Aspirin in the primary and secondary prevention of vascular disease:collaborative meta-analysis of individual participant data from randomised trials[J].Lancet,2009,373(9678):1849-1860.DOI:10.1016/S0140-6736(09)60503-1.
• [16]Wu H,Xu L,Zhao X,et al.Indobufen or aspirin on top of clopidogrel after coronary drug-eluting stent implantation(OPTION):a randomized,openlabel,end point-blinded,noninferiority trial[J].Circulation,2023,147(3):212-222.DOI:10.1161/CIRCULATIONAHA.122.062762.
• [17]Derry S,Loke YK.Risk of gastrointestinal haemorrhage with long term use of aspirin:meta-analysis[J].BMJ,2000,321(7270):1183-1187.DOI:10.1136/bmj.321.7270.1183.
• [18]Sundstrom J,Hedberg J,Thuresson M,et al.Low-dose aspirin discontinuation and risk of cardiovascular events:a swedish nationwide,population-based cohort study[J].Circulation,2017,136(13):1183-1192.DOI:10.1161/CIRCULATIONAHA.117.028321.
• [19]Rebuzzi AG,Natale A,Bianchi C,et al.Effects of indobufen on platelet thromboxane B2 production in patients with myocardial infarction[J].Eur J Clin Pharmacol,1990,39(1):99-100.DOI:10.1007/BF02657071.
• [20]De Caterina R,Giannessi D,Bernini W,et al.A prostacyclinsparing effect of Indobufen vs.Aspirin[J].Thromb Haemost,1996,75(3):510-514.
• [21]Marzo A,Crestani S,Fumagalli I,et al.Endoscopic evaluation of the effects of indobufen and aspirin in healthy volunteers[J].Am J Ther,2004,11(2):98-102.DOI:10.1097/00045 391-200403000-00004.
• [22]Lee JY,Sung KC,Choi HI.Comparison of aspirin and indobufen in healthy volunteers[J].Platelets,2016,27(2):105-109.DOI:10.3109/09537104.2015.1042853.
• [23] Yusuf S,Zhao F,Mehta SR,et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J].N Engl J Med,2001,345(7):494-502.DOI:10.1056/NEJMoa010746.
• [24]Steinhubl SR,Berger PB,Mann JT 3rd,et al.Clopidogrel for the Reduction of Events During Observation.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial[J].JAMA,2002,288(19):2411-2420.DOI:10.1001/jama.288.19.2411.
• [25]Wiviott SD,Braunwald E,McCabe CH,et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2007,357(20):2001-2015.DOI:10.1056/NEJMoa0706482.
• [26]Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2009,361(11):1045-1057.DOI:10.1056/NEJMoa0904327.
• [27]Sch?mig A.Ticagrelor--is there need for a new player in the antiplatelet-therapy field?[J].N Engl J Med,2009,361(11):1108-1111.DOI:10.1056/NEJMe0906549.
• [28]Pereira NL,Cresci S,Angiolillo DJ,et al.CYP2C19 genetic testing for oral P2Y12 inhibitor therapy:a scientific statement from the American Heart Association[J].Circulation,2024,150(6):e129-e150.DOI:10.1161/CIR.0000000000001257.
• [29]Tang YD,Wang W,Yang M,et al.Randomized comparisons of double-dose clopidogrel or adjunctive cilostazol versus standard dual antiplatelet in patients with high posttreatment platelet reactivity:results of the CREATIVE trial[J].Circulation,2018,137(21):2231-2245.DOI:10.1161/CIRCULATIONAHA.117.030190.
• [30]Steffel J,Collins R,Antz M,et al.2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation[J].Europace,2021,23(10):1612-1676.DOI:10.1093/europace/euab065.
• [31]Wiggins BS,Dixon DL,Neyens RR,et al.Select drug-drug interactions with direct oral anticoagulants:JACC review topic of the week[J].J Am Coll Cardiol,2020,75(11):1341-1350.DOI:10.1016/j.jacc.2019.12.068.
• [32]Gurbel PA,Fox KAA,Tantry US,et al.Combination antiplatelet and oral anticoagulant therapy in patients with coronary and peripheral artery disease[J].Circulation,20 19,139(18):2 170-2 185.DOI:10.116 1/CIRCULATIONAHA.118.033580.
• [33]Petzold T,Thienel M,Dannenberg L,et al.Rivaroxaban reduces arterial thrombosis by inhibition of FXa-driven platelet activation via protease activated receptor-1[J].Circ Res,2020,126(4):486-500.DOI:10.1161/CIRCRESAHA.119.315099.
• [34] Bainey KR,Welsh RC,Connolly SJ,et al.Rivaroxaban plus Aspirin versus Aspirin alone in patients with prior percutaneous coronary intervention(COMPASS-PCI)[J].Circulation,2020,141(14):1141-1151.DOI:10.1161/CIRCULATIONAHA.119.0445 98.
• [35]Kang J,Park KW,Palmerini T,et al.Racial differences in ischaemia/bleeding risk trade-off during anti-platelet therapy:individual patient level landmark meta-analysis from seven RCTs[J].Thromb Haemost,2019,119(1):149-162.DOI:10.1055/s-0038-1676545.
• [36]Natsuaki M,Watanabe H,Morimoto T,et al.An aspirin-free versus dual antiplatelet strategy for coronary stenting:STOPDAPT-3randomized trial[J].Circulation,2024,149(8):585-600.DOI:10.1161/CIRCULATIONAHA.123.066720.
• [37]Guimar?es PO,Franken M,Tavares CAM,et al.Early withdrawal of aspirin after PCI in acute coronary syndromes[J].N Engl J Med,2025.DOI:10.1056/NEJMoa2 5 07980.Online ahead of print.
• [38]Valgimigli M,Frigoli E,Heg D,et al.Dual antiplatelet therapy after PCI in patients at high bleeding risk[J].N Engl J Med,2021,385(18):1643-1655.DOI:10.1056/NEJMoa2108749.
• [39]Vranckx P,Valgimigli M,Jüni P,et al.Ticagrelor plus aspirin for 1 month,followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months,followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent:a multicentre,open-label,randomised superiority trial[J].Lancet,2018,392(10151):940-949.DOI:10.1016/S0140-6736(18)31858-0.
• [40]Hahn JY,Song YB,Oh JH,et al.Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention:the SMART-CHOICE randomized clinical trial[J].JAMA,2019,321(24):2428-2437.DOI:10.1001/jama.2019.8146.
• [41]Kim BK,Hong SJ,Cho YH,et al.Effect of ticagrelormonotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome:the TICO randomized clinical trial[J].JAMA,2020,323(23):2407-2416.DOI:10.1001/jama.2020.7580.
• [42]颜红兵,霍勇.经皮冠状动脉介入治疗术后抗血小板治疗2023年度进展[J].中国介入心脏病学杂志,2024,32(1):5-8.DOI:10.3969/j.issn.1004-8812.2024.01.002.
• [43]Watanabe H,Morimoto T,Natsuaki M,et al.Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome:the STOPDAPT-2 ACS randomized clinical trial[J].JAMA Cardiol,2022,7(4):407-417.DOI:10.1001/jamacardio.2021.5244.
• [44]Mehran R,Baber U,Sharma SK,et al.Ticagrelor with or without Aspirin in high-risk patients after PCI[J].N Engl J Med,2019,381(21):2032-2042.DOI:10.1056/NEJMoa1908419.
• [45]Kim CJ,Park MW,Kim MC,et al.Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention(TALOS-AMI):an investigator-initiated,openlabel,multicentre,non-inferiority,randomised trial[J].Lancet,2021,398(10308):1305-1316.DOI:10.1016/S0140-6736(21)01445-8.
• [46]Kim HS,Kang J,Hwang D,et al.Prasugrel-based deescalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome(HOSTREDUCE-POLYTECH-ACS):an open-label,multicentre,non-inferiority randomised trial[J].Lancet,2020,396(10257):1079-1089.DOI:10.1016/S0140-6736(20)31791-8.
• [47]Ge Z,Kan J,Gao X,et al.Ticagrelor alone versus Ticagrelor plus Aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes(ULTIMATE-DA PT):a randomised,placebo-controlled,double-blind clinical trial[J].Lancet,2024,403(10439):1866-1878.DOI:10.1016/S0140-6736(24)00473-2.
• [48]Kang J,Woo K,Han J,et al.Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk(HOST-BR):an open-label,multicentre,randomised clinical trial[J].Lancet,2025.DOI:10.1016/S0140-6736(25)01571-5.
• [49] Costa F,van Klaveren D,James S,et al.Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy(PRECISE-DAPT)score:a pooled analysis of individual-patient datasets from clinical trials[J].Lancet,2017,389(10073):1025-1034.DOI:10.1016/S0140-6736(17)30397-5.
• [50]Yeh RW,Secemsky EA,Kereiakes DJ,et al.Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention[J].JAMA,2016,315(16):1735-1749.DOI:10.1001/jama.2016.3775.
• [51] Urban P,Mehran R,Colleran R,et al.Defining high bleeding risk in patients undergoing percutaneous coronary intervention[J].Circulation,2019,140(3):240-261.DOI:10.1161/CIRCULATIONAHA.119.040167.
• [52]Lee J,Kim MJ,Kim M,et al.Validation of academic research consortium for high bleeding risk definition in east-asian patients[J].JACC Asia,2023,3(3):390-399.DOI:10.1016/j.jacasi.2022.11.012.
• [53]Van Gelder IC,Rienstra M,Bunting KV,et al.2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS)[J].Eur Heart J,2024,45(36):3314-3414.DOI:10.1093/eurheartj/ehae176.
• [54]Xu L,Xu H,Wu S,et al.Indobufen-based dual antiplatelet therapy in patients with multivessel coronary disease undergoing drug-eluting stent implantation insight from the OPTION trial[J].Am Heart J,2025,282:21-29.DOI:10.1016/j.ahj.2024.12.007.
• [55]Koo BK,Kang J,Park KW,et al.Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention(HOST-EXAM):an investigator-initiated,prospective,randomised,open-label,multicentre trial[J].Lancet,2021,397(10293):2487-2496.DOI:10.1016/S0140-6736(21)01063-1.
• [56] Kang J,Park KW,Lee H,et al.Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention:the HOST-EXAM extended study[J].Circulation,2023,147(2):108-117.DOI:10.1161/CIRCULATIONAHA.122.062770.
• [57]Choi KH,Park YH,Lee JY,et al.Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention(SMART-CHOICE 3):a randomised,openlabel,multicentre trial[J].Lancet,2025,405(10486):1252-1263.DOI:10.1016/S0140-6736(25)00449-0.
• [58]Valgimigli M,Choi KH,Giacoppo D,et al.Clopidogrel versus aspirin for secondary prevention of coronary artery disease:a systematic review and individual patient data metaanalysis[J].Lancet,2025,406(10508):1091-1102.DOI:10.1016/S0140-6736(25)01562-4.
• [59]Giacoppo D,Gragnano F,Watanabe H,et al.P2Y12 inhibitor or aspirin after percutaneous coronary intervention:individual patient data meta-analysis of randomised clinical trials[J].BMJ,2025,389:e082561.DOI:10.1136/bmj-2024-082561.
• [60]Gragnano F,Cao D,Pirondini L,et al.P2 Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events[J].J Am Coll Cardiol,2023,82(2):89-105.DOI:10.1016/j.jacc.2023.04.051.
• [61]Gimbel M,Qaderdan K,Willemsen L,et al.Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome(POPular AGE):the randomised,open-label,non-inferiority trial[J].Lancet,2020,395(10233):1374-1381.DOI:10.1016/S0140-6736(20)30325-1.
• [62] Wu H,Wang Q,Zhou J,et al.First report of stent thrombosis after a switch therapy resulting from ticagrelor-related dyspnea[J].Int J Cardiol,2014,176(3):e127-e128.DOI:10.1016/j.ijcard.2014.07.216.
• [63]Bonaca MP,Bhatt DL,Cohen M,et al.Long-term use of ticagrelor in patients with prior myocardial infarction[J].N Engl J Med,2015,372(19):1791-1800.DOI:10.1056/NEJMoa1500857.
• [64] Storey RF,Angiolillo DJ,Bonaca MP,et al.Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUSTIMI 54 trial[J].J Am Coll Cardiol,2016,67(10):1145-1154.DOI:10.1016/j.j acc.2015.12.062.
• [65]Dai C,Liu M,Yang Z,et al.Real-world performance of indobufen versus aspirin after percutaneous coronary intervention:insights from the ASPIRATION registry[J].BMC Med,2024,22(1):148.DOI:10.1186/s12916-024-03374-3.
• [66]Bonaca MP,Im K,Magnani G,et al.Patient selection for long-term secondary prevention with ticagrelor:insights from PEGASUS-TIMI 54[J].Eur Heart J,2022,43(48):5037-5044.DOI:10.10 9 3/eurheartj/ehac402.
• [67]Li Y,Li J,Wang B,et al.Extended clopidogrel monotherapy vs DAPT in patients with acute coronary syndromes at high ischemic and bleeding risk:the OPT-BIRISK randomized clinical trial[J].JAMA Cardiol,2024,9(6):523-531.DOI:10.1001/jamacardio.2024.0534.